Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ANI Pharmaceuticals, Inc. (Nasdaq: ANIP), a diversified biopharmaceutical company focused on rare disease, generics, and branded therapeutics. Through these filings, investors can review how ANI reports its financial results, capital structure changes, and other material events related to its Rare Disease, Generics, and Brands businesses.
ANI frequently files Form 8-K current reports to disclose quarterly and year-to-date financial results, updated investor presentations, and other significant developments. For example, recent 8-K filings reference press releases announcing results for specific quarters, updated guidance, and the publication of investor presentations that describe the company’s strategy, segment performance, and focus on products such as Purified Cortrophin Gel and ILUVIEN. Other 8-K filings discuss matters like the conversion of Series A Convertible Preferred Stock into common shares and updates on litigation outcomes.
In addition to 8-Ks, investors can use this filings page to locate ANI’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide more detailed discussions of segment results, risk factors, product portfolios, and the company’s rare disease strategy. These periodic reports elaborate on how ANI’s Rare Disease, Generics, and Brands businesses contribute to overall performance and outline risks related to manufacturing, regulatory approvals, competition, and market conditions.
Filings related to equity and capital structure are also important for ANIP. For instance, the company has reported on the issuance and subsequent conversion of Series A Convertible Preferred Stock, including dividend terms and conversion conditions, and on the issuance of common shares upon conversion under exemptions from registration. Such disclosures help investors understand changes in outstanding securities and potential dilution.
Stock Titan enhances this information by offering AI-powered summaries of ANI’s key filings. These summaries highlight the main points from lengthy documents, such as revenue trends, segment performance, major product updates, and notable legal or corporate events. Users can quickly scan 10-Ks, 10-Qs, and 8-Ks, and then dive into the full text on EDGAR for deeper analysis. The filings page also surfaces information relevant to insider and security-holder activity where reported, enabling a more complete view of ANI Pharmaceuticals’ regulatory and financial disclosures.
ANI Pharmaceuticals (ANIP) reported insider transactions by its SVP – Corp. Dev. & Strategy. On 11/12/2025, the reporting person sold 14,642 shares of common stock at a weighted average price of $89.07, with trades ranging from $89.00 to $89.50. On 11/13/2025, an additional 94 shares were sold at $88.00.
Following these transactions, the filer beneficially owned 73,615 shares directly and 158,490 shares indirectly through Chali Properties LLC, over which the reporting person holds voting and dispositive power.
ANI Pharmaceuticals furnished an updated investor presentation to the investor relations section of its website and attached it as Exhibit 99.1. The presentation is dated November 2025 and may be used in meetings with investors, analysts, and others.
The materials were provided under Items 2.02 and 7.01 and are expressly designated as furnished, not filed, under the Exchange Act, and are not subject to Section 18 liabilities or incorporated into other filings unless specifically referenced.
ANI Pharmaceuticals (ANIP) reported strong Q3 2025 results. Net revenues were $227.8 million, up from $148.3 million a year ago. Net income was $26.6 million versus a loss of $24.2 million, and diluted EPS was $1.13. Operating income reached $36.2 million, helped by higher sales in Rare Disease and Brands, especially Cortrophin Gel and the addition of ILUVIEN and YUTIQ.
Year-to-date, net revenues were $636.3 million versus $423.8 million. Operating cash flow was $154.9 million. Cash and cash equivalents were $262.6 million as of September 30, 2025. The company completed the Alimera acquisition in 2024 and in March 2025 expanded ILUVIEN’s U.S. label to include NIU-PS, shifting U.S. promotion from YUTIQ to ILUVIEN. As of October 31, 2025, there were 22,458,168 shares of common stock outstanding.
ANI Pharmaceuticals, Inc. filed a current report to note that it has released its financial results for the third quarter ended September 30, 2025. The company announced these results in a press release dated November 7, 2025, which is included as Exhibit 99.1. The report clarifies that the information about these quarterly results is being furnished rather than filed, meaning it is not subject to certain liability provisions under securities law unless specifically incorporated into other filings.
ANI Pharmaceuticals (ANIP) reported an insider transaction on a Form 4. Senior Vice President, General Counsel & Secretary Meredith W. Cook sold 400 shares of common stock on 10/13/2025 at $90.09 per share under a Rule 10b5-1 trading plan adopted on September 17, 2024.
Following the sale, Cook beneficially owns 75,674 shares, held directly. This filing reflects routine insider activity disclosed for transparency.
ANI Pharmaceuticals, Inc. disclosed that all of its Series A Convertible Preferred Stock held by Ampersand 2020 Limited Partnership has been converted into common stock. Ampersand originally purchased 25,000 Preferred Shares in 2021 for an aggregate $25 million, with the shares carrying a 6.50% cumulative dividend and conversion features set out in a Certificate of Designation.
On August 14, 2025, Ampersand optionally converted 5,000 Preferred Shares into 120,580 common shares at a conversion price of $41.4662 per share. On September 26, 2025, after specified stock price conditions were met, ANI mandatorily converted the remaining 20,000 Preferred Shares into 482,320 common shares at the same conversion price.
In total, the conversions exchanged all 25,000 Preferred Shares for 602,900 common shares, leaving no Preferred Shares outstanding. The common shares issued in these exchanges relied on the Section 3(a)(9) exemption under the Securities Act for transactions with existing security holders without paid solicitation.
ANI Pharmaceuticals officer Krista Davis reported a sale of 1,000 shares of ANIP common stock on 09/19/2025 at a price of $98.04 per share. The sale was executed under a Rule 10b5-1 trading plan adopted August 23, 2024. After the transaction, the reporting person beneficially owns 60,186 shares, held directly. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person and records the transaction as a routine, preplanned disposition under the company insider trading plan.
Krista Davis, SVP and Chief HR Officer of ANI Pharmaceuticals (ANIP), reported a tax-withholding disposition tied to the vesting of restricted stock. On 09/12/2025 she disposed of 1,710 shares of common stock at a price of $97.71 per share; following the transaction she beneficially owns 61,186 shares. The filing notes those shares were withheld to satisfy tax obligations related to the vesting of 4,108 previously granted restricted shares.
The Form 4 was signed via attorney-in-fact on 09/15/2025. This is a routine, non-derivative withholding to cover taxes on vested restricted stock rather than an open-market sale or a new transfer of ownership.
Meredith W. Cook, Senior Vice President, General Counsel & Secretary of Ani Pharmaceuticals (ANIP), reported a sale of 400 shares of the company on 09/12/2025 at a price of $98.42 per share. After the transaction she beneficially owned 76,074 shares. The filing states the sale was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on 09/17/2024, indicating the trade followed an automated plan rather than an ad‑hoc decision. The Form 4 was signed by Ms. Cook on 09/15/2025.
ANI Pharmaceuticals, Inc. filed a current report noting that President & CEO Nikhil Lalwani and the executive leadership team will present at two upcoming investor conferences in New York City. They are scheduled to speak at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025.
The company prepared an updated investor presentation for these events, dated September 2025, and may use it in future meetings with investors and analysts. This presentation is provided as Exhibit 99.1 and is furnished, rather than filed, meaning it is not subject to certain liability provisions under securities laws unless specifically incorporated into other filings.